NCT05164536View on ClinicalTrials.gov

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

PHASE1CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

November 8, 2022

Study Completion Date

November 8, 2022

Conditions

Alzheimer Disease

Interventions

DRUG

Amyvid

All participants will undergo a single β-amyloid PET scan with Amyvid.

Trial Locations (1)

06510

Invicro, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Invicro

OTHER

NCT05164536 - Plasma P-tau2017 and Quantitative Amyloid PET Imaging | Biotech Hunter | Biotech Hunter